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ERCP; (5) fibrotic change with histopatho-logic lym-
phocytic infiltration; (6) absence of symptoms or only
mild symptoms, usually with an absence of acute
attacks of pancreatitis; (7) constriction of the common
bile duct in the pancreas with proximal dilatation, and
frequent cholestasis and hyperbilirubinaemia; (8) no
pancreatic calcification; (9) no pancreatic cysts; (10)
occasional association with other autoimmune dis-
eases; and (11) effectiveness of steroid therapy [2].
This condition has also been named sclerosing pan-
creatitis and idiopathic fibrosing pancreatitis [3,4].
Autoimmune pancreatitis has been described in asso-
ciation with Sjo¨gren syndrome, Crohn’s disease and
ulcerative colitis [5]. Its incidence in Japan is 5.93
patients per 100 000 inhabitants per year, with a
prevalence of 4.78 patients per 100 000 inhabitants
[6]. Sjo¨gren syndrome was associated with 25% of the
cases of autoimmune pancreatitis in a review of 40
institutions in Japan [7]. The second most common
associated disease was primary sclerosing cholangitis
(13%), followed by systemic lupus erithematodes.
In line with the Japanese criteria for the diagnosis of
autoimmune pancreatitis, our patient had obstruc-
tive jaundice secondary to fibrosing pancreatitis, with
a probable autoimmune aetiology associated with
ulcerative colitis. In some patients with Crohn’s
disease and ulcerative colitis, this condition has been
associated with antibodies against pancreatic juice [8].
Other authors have found high serum IgG4 concen-
trations, suggesting an autoimmune pathogenesis [9].
Glucocorticoid therapy induces clinical remission and
would be the first-line treatment [6,9], although many
patients require subsequent operation [3].
Autoimmune pancreatitis should be considered
in young patients with obstructive jaundice [10],
especially those affected with chronic inflammatory
or autoimmune diseases [11].
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Abstract
Background. First described in 1988, attenuated familial adenomatous polyposis (AFAP) is a rare autosomal dominant
precancerous condition of the gastrointestinal tract. Few reports have described adenocarcinomatous change in the
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gastroduodenal region thus far. Case outline. We report a case of AFAP presenting with extensive gastric polyposis and
ampullary adenocarcinoma in absence of a positive family history of gastrointestinal cancer and a novel mutation.
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Case report
A 35-year-old man was referred to us for evaluation of
his abnormal liver enzymes. Gamma-glutamyl trans-
peptidase (g-GT) level had risen to over 2000 IU/L
and his CA 19-9 level was /1000 kU/L. Magnetic
resonance (MR)-cholangiography showed the com-
mon bile duct to be slightly dilated but no stone or
tumour was identified. Upper gastrointestinal endo-
scopy showed multiple gastric polyps within the
proximal two-thirds of the stomach and a friable
1/2-cm villous polyp at the ampulla of Vater. Gastric
biopsy revealed foveolar hyperplasia with atypia sug-
gestive of adenomatous change and biopsy of the
ampullary lesion showed severe dysplasia. At colono-
scopy seven small non-malignant adenomatous polyps
were removed from the left colon. Fundoscopy
revealed multiple, bilateral congenital hypertrophy of
retinal pigment epithelium (CHRPE) lesions.
The presence of widespread adenomatous lesions
within the body and fundus and their potential for
malignant transformation in view of his age, led us to
perform a total gastrectomy and pancreaticoduo-
denectomy with a Roux-en-Y reconstruction. Histol-
ogy of the resected ampullary lesion revealed foci of
well-differentiated adenocarcinoma with microinva-
sion of the stroma.
The patient was referred for genetic counselling.
There was no family history of bowel cancer or polyps.
The limited extent of involvement of the colon was
consistent with AFAP. He was found to have the
G126X mutation in exon 3 of the APC gene. This
particular truncating mutation has not been described
previously [1].
A CT scan at 9 months showed no signs of
recurrence of his ampullary tumour. Follow-up colo-
noscopy at 1 year post surgery revealed normal
mucosa and a biopsy taken from terminal ileum was
identified as normal.
Discussion
AFAP is a rare precancerous condition of the gastro-
intestinal tract. Few reports have described adenocar-
cinomatous change in the gastroduodenal region thus
far [2,3]. AFAP is a milder variant of familial
adenomatous polyposis (FAP) transmitted in an
autosomal dominant fashion [4]. It is caused by
mutations clustered either at the far 5? end (before
codon 536) or at the 3? end (after codon 1596) of the
APC gene [5]. Individuals with AFAP develop fewer
polyps (average 40/50) and have a later onset of
diagnosis of bowel cancer, at a mean age of 56 years
[4,6]. AFAP usually affects the proximal colon with
sparing of the rectum [4]. CHRPE is the most
common extraintestinal finding in FAP. It is an oval
pigmented lesion surrounded by a pale halo. They are
rarely reported in AFAP patients, particularly AFAP
patients with mutations in the 5? part of the APC gene
[7]; 25% of AFAP cases arise sporadically while
others may have affected siblings with unaffected
parents. Such cases might result from a new APC
gene mutation or gonadal mosaicism in a clinically
unaffected parent [8]. While the correlation between
the location of APC (adenomatosis polyposis coli)
germline mutation and the development of AFAP has
been well documented, the mechanism for AFAP
remains to be elucidated [9,10].
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